Angiogenic activity of sera from patients with systemic autoimmune diseases in relation to clinical, radiological, and functional pulmonary status

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 791-800

  Zielonka, T M ^a,b   Demkow, U ^b   Zycinska, K ^a   Filewska, M ^c   Korzeniewska, M ^c   Radzikowska, E ^c   Bialas Chromiec, B ^c   Kus, J ^c   Wardyn, K A ^a   Skopinska Rozewska, E ^b  

^a Department of Family Medicine ^*  (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Angiogenesis; Collagen diseases; Systemic sclerosis; Wegener's granulomatosis

Indexed keywords

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; QUESTIONNAIRE; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; WEGENER GRANULOMATOSIS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COLLAGEN DISEASE; COUGHING; IMMUNOLOGY; MIDDLE AGED; MONOCYTE; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; RADIOGRAPHY; SPIROMETRY;

ADULT; ANIMALS; AUTOIMMUNE DISEASES; COLLAGEN DISEASES; COUGH; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PLETHYSMOGRAPHY; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SPIROMETRY; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 64549149719     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Yi ES, Colby TV. Wegener's granulomatosis. Semin Diagn Pathol 2001; 18: 34-46.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the managements of rheumatoid arthritis. Arthritis Rheum 2002; 46: 328-346.
3. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996; 22: 675-694.
4. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979; 346: 1326-1335.
5. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
6. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999; 103: 3-4.
7. Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000; 59 Suppl 1: S65-S71.
8. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-1107.
9. D'Alessio S, Fibbi G, Cinelli M et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50: 3275-3285.
10. Ihn H, Sato S, Fujimoto M et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000; 119: 203-209.
11. Jackson J, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-465.
12. Wagner EM, Sanchez J, McClintock JY, Jenkins J, Moldobaeva A. Inflammation and ischemia- induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 2008; 294: 351-357.
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
14. Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Eur Respir J1993; 6: 5-40.
15. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-versus-host reaction. J Exp Med 1975; 141: 84-100.
16. Zielonka TM, Demkow U, Bialas B et al. Modulatory effect of sera from sarcoidosis patients on mononuclear cells-induced angiogenesis. J Physiol Pharmacol 2007; 58 Suppl 5: 753-766.
17. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6: 357-376.
18. Hirohata S, Sakakibara J. Angiogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet 1999; 353: 1331-1331.
19. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000; 80: 1195-1205.
20. Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Investig Med 1998; 46: 27-41.
21. Koch AE, Kunkel SL, Harlow LA et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94: 1012-1018.
22. JanssenBA, Luqmani RA, Gordon C et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33: 1112-1116.
23. Narumi S, Takeuchi T, Kobayashi Y, Konishi K. Serum levels of INF inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000; 12: 1561-1565.
24. Detmar M, Brown LF, Claffey KP et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141-1146.
25. Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH. The predominance of beta (CC) chemokines transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997; 109: 275-285.
26. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunological parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000; 39: 383-388.
27. Majewski S, Skopinska-Rozewska E, Jablonska S et al. Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum 1985; 28: 1133-1139.
28. Konttinen YT, Mackiewicz Z, Ruuttila P et al. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 2003; 22: 196-202.
29. Distler O, del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11. Published online 2002 August 30.
30. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139: 1049-1051.
31. Mackiewicz Z, Sukura A, Povilenaité D et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 2002; 20: 641-646.
32. Yamaguchi N, Anand-Apte B, Lee M et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414-4423.
33. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 889-893.
34. Mulligan-Kehoe MJ, Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 2007; 9: 173-179.
35. Giusti B, Serrati S, Margheri F et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005; 52: 3618-3628.
36. Giusti B, Fibbi G, Margheri F et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006; 8: R115. Epub2006 Jul19.
37. Terai M, Yasukawa K, Narumato S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999; 83: 337-339.
38. Li CG, Reynolds I, Ponting JM, Holt PJ, Hillarby MC, Kumar S. Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener's granulomatosis. Br J Rheumatol 1998; 37: 1303-1306. 39. Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101: 387-394.
39. Griffith ME, Coulthart A, Pemberton S, George AJ, Pusey CD. Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin Exp Immunol 2001; 123: 170-177.
40. Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, α1-antitrypsin, and Fcy receptors. J Clin Invest 1997; 100: 1416-1424.
41. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993; 91: 977-985.